Phase 2 Bladder Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 18 and 75 years old at the time of signing the consent form, regardless of gender
- You are generally well enough to carry out daily activities with little or no limitation, and doctors expect you to live for more than 6 months
- Tests have confirmed you have locally advanced bladder cancer (a specific type called urothelial carcinoma) that has not spread to distant parts of the body
- You are considered a suitable candidate and are planning to have surgery to remove your bladder (radical cystectomy)
- At least one area of cancer can be clearly measured on a CT scan
- You have not received any cancer treatment through the bloodstream (such as chemotherapy or immunotherapy) since being diagnosed with this bladder cancer
- Your blood test results show that your blood cells, kidneys, liver, and thyroid are all functioning within acceptable levels (checked within 2 weeks before starting the trial)
- If you are a woman who could become pregnant, you must have a negative pregnancy test within 7 days of joining and agree to use reliable contraception during the trial and for 8 weeks after the last dose
- You agree to provide tumour tissue samples for research purposes and to attend all planned appointments
- You are willing and able to sign a consent form agreeing to take part
Who may not be able to join:
- You have previously received certain types of immunotherapy (anti-PD1, PDL1, or CTLA-4 drugs) or chemotherapy given through the bloodstream (bladder wash-in chemotherapy does not count)
- You have received a BCG bladder treatment within the last 4 weeks
- You have previously had radiotherapy directed at your bladder
- You have or have had an active autoimmune disease (a condition where the immune system attacks the body)
- You need to take immunosuppressant medications, or have been taking steroid tablets above a low dose within 2 weeks before starting the trial
- You currently have or have had another type of cancer at the same time
- You have had an allergic reaction to any antibody-based drug in the past
- You have a history of HIV infection
- You currently have an active infection, including active tuberculosis
- You have a serious heart condition, or your heart failure has been rated as severe by a doctor (confirm with trial site)
- You have had a kidney transplant
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Abai Xu, doctor, Zhujiang Hospital
Phone: +86 18665626790
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Pathological response rate evaluated after 4 cycles of neoadjuvant Toripalimab in combination with gemcitabine and cisplatin at time of radical cystectomy, each cycle is 21 days
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.